(164) mRNA-Lipid Nanoparticle Formulations for Targeted Drug Delivery as Cancer Vaccines
Introduction: After their success with COVID-19 vaccines, the interest in messenger RNA (mRNA)-based therapies has grown unprecedentedly. Leveraging this advancement, mRNA encapsulated within lipid nanoparticle (LNP) delivery systems has emerged as a promising strategy for various purposes, such as cancer vaccines used therapeutically while delivering a cancer biomarker. Our experimental work involved optimizing formulation parameters to enhance the cytocompatibility and minimize its cytotoxic effects, to translate tumor-specific antigen mRNA into protein and bind to its target efficiently.
Learning Objectives:
Optimize the biocompatibility of LNP-mRNA formulation and pharmacological properties in HEK293 cells
Evaluate the formulation candidates for the selected tumor-specific antigen delivery in HEK293 cells
Explain advantages of using LNP-mRNA formulations as a drug delivery mechanism in cancer treatment
